Piermont Capital Management’s Haemonetics HAE Stock Holding History

Piermont Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-45,187	Closed	-$4.05M	–	148
2018 Q2	$4.05M	Sell	45,187 -10,160	-18%	-$858K	1.24%	2
2018 Q1	$4.05M	Buy	55,347 +1,250	+2%	+$85.8K	1.35%	2
2017 Q4	$3.14M	Sell	54,097 -1,750	-3%	-$92.1K	1.03%	8
2017 Q3	$2.51M	Hold	55,847	–	–	0.83%	25
2017 Q2	$2.21M	Sell	55,847 -14,470	-21%	-$594K	0.63%	49
2017 Q1	$2.85M	Sell	70,317 -7,000	-9%	-$273K	0.68%	44
2016 Q4	$3.11M	Sell	77,317 -5,920	-7%	-$223K	0.71%	42
2016 Q3	$3.01M	Sell	83,237 -1,260	-1%	-$43.3K	0.71%	41
2016 Q2	$2.45M	Hold	84,497	–	–	0.63%	64
2016 Q1	$2.96M	Sell	84,497 -2,060	-2%	-$66.5K	0.94%	22
2015 Q4	$2.79M	Buy	+86,557	New	+$2.81M	0.89%	41

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Piermont Capital Management's HAE Position: Q3 2018 in Review

Piermont Capital Management sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 45,187 shares — an estimated $4.05M sold.

Piermont Capital Management first reported a position in HAE in Q4 2015 and held it in 11 quarters. The position peaked at $4.05M in Q2 2018. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

Piermont Capital Management reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
Piermont Capital Management sold 45,187 Haemonetics shares in Q3 2018, an estimated $4.05M.
Piermont Capital Management first reported a position in Haemonetics in Q4 2015 and held it in 11 quarters.
Piermont Capital Management's Haemonetics position peaked at $4.05M in Q2 2018.
292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.